---

Safety and efficacy of duloxetine versus gabapentin in painful diabetic polyneuropathy

Full Text PDF

---

Original Article

Author Details : Tamilsetti Vidya Sagar, Byndoor Yatish*

Volume : 7, Issue : 4, Year : 2022

Article Page : 223-227

https://doi.org/10.18231/j.ijcaap.2022.042

Suggest article by email

Get Permission

Abstract

Objective: To evaluate safety and efficacy of Gabapentin and Duloxetine in patients with painful diabetic neuropathy.
Materials and Methods: This is a prospective randomized double blinded parallel group study done for a period of 12 weeks. Total of 60 patients were enrolled and randomly allocated to two groups with 30 patients each, group A received Duloxetine 30 mg twice daily and group B received Gabapentin 300mg twice daily and followed every 2 weeks. Patients of age 35 to 60 years with painful diabetic peripheral polyneuropathy are included in the study. Primary objective is improvement in pain assessed by NPRS; Secondary objective is improvement in sleep and clinical condition of the patient, assessed by Sleep Interference Score and Clinical Global Impression of Change (CGIC). Assessment was done at beginning and at four, eight and twelve weeks. Data was analysed using SPSS 12.0 version.
Results: Numerical pain rating scores and daily sleep interference scores were reduced significantly with course of treatment within both groups (p = <0 xss=removed> Conclusion: Monotherapy with either Duloxetine or Gabapentin was equally effective at 12 weeks treatment with minor side effects. In addition, Gabapentin showed fewer side effects. It can be concluded that for preventing side effects, Gabapentin can be used. Further large head to- head comparator and combination trials are required.

Keywords: Numerical pain rating scale (NPRS), Clinical Global Impression Change score(CGIC), Daily sleep interference score(DSIS), Duloxetine and Gabapentin

How to cite : Sagar T V, Yatish B, Safety and efficacy of duloxetine versus gabapentin in painful diabetic polyneuropathy. IP Int J Compr Adv Pharmacol 2022;7(4):223-227

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.